Promising Results in New Cancer Treatment Studies

In depth

An international study presented at the European Cancer Congress examined a combined treatment with two immunotherapy drugs for patients with small cell lung cancer. The treatment reduced the risk of mortality by 58%, according to Israel Hayom.

According to Walla, the DeLLphi-305 study tested a combination of tarlatamab, marketed under the name Imdelltra, with durvalumab, known by its brand name, and the drug directs the immune system's cells toward the tumor before the disease resumes progressing. According to Ynet, the price in the US stands at more than 1.2 million shekels per year.